Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study

被引:201
作者
Swerdlow, AJ [1 ]
Higgins, CD
Adlard, P
Preece, MA
机构
[1] Inst Canc Res, Epidemiol Sect, Sutton SM2 5NG, Surrey, England
[2] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London, England
[3] Inst Child Hlth, Biochem Endocrinol & Metab Unit, London, England
基金
英国医学研究理事会;
关键词
D O I
10.1016/S0140-6736(02)09519-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Growth hormone raises serum concentrations of insulin-like growth factor IGFI, which is mitogenic and antiapoptotic. There is evidence that raised endogenous levels of growth hormone and IGFI might be associated with increased risk of certain solid cancers, but there have been no data on long-term risks of solid cancers after growth hormone treatment. Methods We did a cohort study to investigate cancer incidence and mortality in 1848 patients in the UK who were treated during childhood and early adulthood with human pituitary growth hormone during the period from 1959 to 1985. Patients were followed up for cancer incidence to December, 1995 and for mortality to December, 2000. Risk of cancer in the cohort was compared with that in the general population, controlling for age, sex, and calendar period. Findings Patients treated with human pituitary growth hormone had significantly raised risks of mortality from cancer overall (standardised mortality ratio 2.8, 95% CI 1.3-5.1; ten cases), colorectal cancer (10.8, 1.3-38.8; two cases), and Hodgkin's disease (11.4, 1.4-41.3; two cases). Incidence of colorectal cancer was also greatly raised (7.9, 1.0-28.7). After exclusion of patients whose original diagnosis rendered them at high risk of cancer, the significance and size of the risks of colorectal cancer incidence and mortality, and of Hodgkin's disease mortality were increased. Interpretation Although based on small numbers, the risk of colorectal cancer is of some concern and further investigation in other cohorts is needed. We have no evidence as to whether growth hormone in modern dosage regimens is associated with an increased risk of colorectal cancer.
引用
收藏
页码:273 / 277
页数:5
相关论文
共 34 条
[1]   Risk of leukemia in children treated with human growth hormone: Review and reanalysis [J].
Allen, DB ;
Rundle, AC ;
Graves, DA ;
Blethen, SL .
JOURNAL OF PEDIATRICS, 1997, 131 (01) :S32-S36
[2]  
[Anonymous], 1997, INT CLASSIFICATION D
[3]  
[Anonymous], 1987, Statistical methods in cancer research, Vol 1-The analysis of case-control studies
[4]   One year growth hormone replacement therapy does not alter colonic epithelial cell proliferation in growth hormone deficient adults [J].
Beentjes, JAM ;
van Gorkom, BAP ;
Sluiter, WJ ;
de Vries, GE ;
Kleibeuker, JH ;
Dullaart, RPF .
CLINICAL ENDOCRINOLOGY, 2000, 52 (04) :457-462
[5]   Safety of recombinant deoxyribonucleic acid-derived growth hormone: The national cooperative growth study experience [J].
Blethen, SL ;
Allen, DB ;
Graves, D ;
August, G ;
Moshang, T ;
Rosenfeld, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (05) :1704-1710
[6]   MORTALITY, NEOPLASIA, AND CREUTZFELDT-JAKOB DISEASE IN PATIENTS TREATED WITH HUMAN PITUITARY GROWTH-HORMONE IN THE UNITED-KINGDOM [J].
BUCHANAN, CR ;
PREECE, MA ;
MILNER, RDG .
BRITISH MEDICAL JOURNAL, 1991, 302 (6780) :824-828
[7]  
Cats A, 1996, CANCER RES, V56, P523
[8]   Plasma insulin-like growth factor I and prostate cancer risk: A prospective study [J].
Chan, JM ;
Stampfer, MJ ;
Giovannucci, E ;
Gann, PH ;
Ma, J ;
Wilkinson, P ;
Hennekens, CH ;
Pollak, M .
SCIENCE, 1998, 279 (5350) :563-566
[9]  
Christiansen JS, 2001, J CLIN ENDOCR METAB, V86, P1868
[10]   RISK OF LEUKEMIA AFTER TREATMENT WITH PITUITARY GROWTH-HORMONE [J].
FRADKIN, JE ;
MILLS, JL ;
SCHONBERGER, LB ;
WYSOWSKI, DK ;
THOMSON, R ;
DURAKO, SJ ;
ROBISON, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (23) :2829-2832